Data / Research funding / Brain Cancer
Brain Cancer: 1,448 NIH awards ($1.6B) to 274 organizations
1,448 NIH awards ($1.6B) in the NIH spending category Brain Cancer, to 274 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,448 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NRG Oncology NCORP Research Base-BIQSFP | NIH | National Cancer Institute | 2021 to 2025 | $54,340,726 | July 11, 2025 | July 31, 2026 | BRUNER, DEBORAH WATKINS | reporter.nih.gov |
| Oklahoma IDeA Network of Biomedical Research Excellence | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $19,194,069 | September 6, 2001 | August 31, 2030 | LANG, MARK L | reporter.nih.gov |
| Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors | NIH | National Cancer Institute | 2021 to 2025 | $18,653,803 | April 1, 1999 | March 31, 2026 | ONAR-THOMAS, ARZU | reporter.nih.gov |
| Cancer Center Support (CORE) Grant | NIH | National Cancer Institute | 2021 to 2025 | $11,628,123 | August 1, 1997 | June 30, 2030 | PALUCKA, ANNA KAROLINA | reporter.nih.gov |
| SPORE in Brain Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,413,880 | September 1, 2008 | August 31, 2029 | LANG, FREDERICK F | reporter.nih.gov |
| Sex-based Differences in Glioma | NIH | National Cancer Institute | 2021 to 2025 | $8,258,328 | September 14, 2020 | December 31, 2026 | LATHIA, JUSTIN D. | reporter.nih.gov |
| Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $6,769,276 | March 1, 2021 | August 31, 2027 | KAHALLEY, LISA SCHUM | reporter.nih.gov |
| Understanding the role of tumor microenvironment in low grade glioma progression to malignancy | NIH | National Cancer Institute | 2024 to 2025 | $5,275,940 | September 1, 2024 | August 31, 2029 | CAI, LONG | reporter.nih.gov |
| The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,965,167 | September 21, 2021 | August 31, 2028 | HOLLAND, ERIC C. | reporter.nih.gov |
| Mutations of Chromatin and its Modifying Machineries in Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $4,635,274 | August 13, 2015 | August 31, 2029 | SHILATIFARD, ALI | reporter.nih.gov |
| A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform | NIH | National Center for Advancing Translational Sciences | 2021 to 2024 | $4,598,428 | July 1, 2021 | April 30, 2026 | HINGTGEN, SHAWN | reporter.nih.gov |
| Rates and mechanisms of age-related somatic mutation in normal and Alzheimer brain | NIH | National Institute on Aging | 2021 to 2025 | $4,268,929 | April 1, 2021 | September 30, 2026 | WALSH, CHRISTOPHER A. | reporter.nih.gov |
| Neuronal and Network Mechanisms of Electrocortical Stimulation | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $4,175,793 | August 15, 2023 | July 31, 2026 | SLUTZKY, MARC W. | reporter.nih.gov |
| Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights | NIH | National Cancer Institute | 2022 to 2025 | $4,071,173 | June 1, 2022 | May 31, 2027 | ZHANG, BING | reporter.nih.gov |
| Mechanisms of chromosome segregation, aneuploidy, and tumorigenesis | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $4,006,479 | May 1, 2017 | August 31, 2027 | CLEVELAND, DON W | reporter.nih.gov |
| Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | NIH | National Cancer Institute | 2021 to 2025 | $3,999,763 | June 1, 2013 | August 31, 2026 | RINGOLD, GORDON M | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Characterizing germline and somatic alterations by glioma subtypes and clinical outcome | NIH | National Cancer Institute | 2021 to 2023 | $3,952,018 | May 9, 2019 | April 30, 2026 | BONDY, MELISSA L. | reporter.nih.gov |
| Preclinical development of breakthrough immunotherapy for brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,949,492 | December 15, 2017 | November 30, 2025 | OKADA, HIDEHO | reporter.nih.gov |
| The power of extracellular vesicles in glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $3,947,064 | September 6, 2018 | August 31, 2025 | BREAKEFIELD, XANDRA OWENS | reporter.nih.gov |
| CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,903,008 | January 1, 2021 | December 31, 2025 | WEISS, WILLIAM A | reporter.nih.gov |
| In vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models | NIH | National Cancer Institute | 2021 to 2025 | $3,829,886 | July 14, 2015 | June 30, 2026 | LI, XIAONAN | reporter.nih.gov |
| Image-based models of tumor-immune dynamics in glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,775,245 | March 1, 2021 | February 28, 2027 | HU, LELAND | reporter.nih.gov |
| Proteogenomic translator for cancer biomarker discovery towards precision medicine | NIH | National Cancer Institute | 2022 to 2025 | $3,707,896 | May 1, 2025 | April 30, 2026 | WANG, PEI | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| Evolution of gliomas during treatment and resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,464,231 | April 1, 2015 | June 30, 2026 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| Oncogenic mechanisms, molecular stratification and therapeutic targets of brain tumors | NIH | National Cancer Institute | 2022 to 2025 | $3,447,832 | September 24, 2021 | August 31, 2028 | IAVARONE, ANTONIO | reporter.nih.gov |
| Cell Identity Determination in Human Brain: Somatic Mutation and Cell Lineage | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,434,150 | December 16, 1994 | June 30, 2030 | WALSH, CHRISTOPHER A. | reporter.nih.gov |
| Chemical tools for developmental biology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,426,216 | April 1, 2018 | June 30, 2028 | CHEN, JAMES K | reporter.nih.gov |
| Perivascular tissue models to overcome MGMT-mediated temozolomide resistance in glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,357,689 | December 1, 2020 | November 30, 2026 | HARLEY, BRENDAN A. | reporter.nih.gov |
| Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment. | NIH | National Cancer Institute | 2021 to 2025 | $3,347,022 | July 1, 2021 | June 30, 2026 | MISCHEL, PAUL S | reporter.nih.gov |
| The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,320,824 | June 15, 2021 | March 31, 2027 | MUNSON, JENNIFER M | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Stroger Hospital of Cook County (SHCC) MU-NCORP Renewal | NIH | National Cancer Institute | 2021 to 2024 | $3,305,824 | August 16, 2014 | March 31, 2025 | TAMKUS, DEIMANTE | reporter.nih.gov |
| Theranostics for Pediatric Brain Cancer | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,299,320 | April 15, 2021 | January 31, 2027 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas | NIH | National Cancer Institute | 2021 to 2025 | $3,294,656 | August 6, 2021 | July 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Multimodality Neuroimaging Evaluation of Cognitive Functioning in Lower Grade Astrocytoma | NIH | National Cancer Institute | 2022 to 2025 | $3,280,932 | September 9, 2022 | August 31, 2027 | LI, YAN | reporter.nih.gov |
| Imaging-based tumor forecasting to predict brain tumor progression and response to therapy | NIH | National Cancer Institute | 2022 to 2025 | $3,208,620 | September 19, 2022 | August 31, 2028 | QUARLES, CHRISTOPHER CHAD | reporter.nih.gov |
| Isolation, characterization and translational development of glioma stem cells | NIH | National Cancer Institute | 2021 to 2023 | $3,189,696 | February 1, 2017 | January 31, 2025 | PARADA, LUIS FERNANDO | reporter.nih.gov |
| Magnetic Resonance Fingerprinting of Glutamate Metabolism for Guiding Glioma Cancer Care | NIH | National Cancer Institute | 2025 | $3,155,815 | August 14, 2025 | July 31, 2029 | PAECH, DANIEL | reporter.nih.gov |
| Integration and interoperability of complex data and tissues from the human brain | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $3,131,401 | September 20, 2023 | December 31, 2026 | LOEB, JEFFREY A | reporter.nih.gov |
| Multi-scale modeling of glioma for the prediction of treatment response, treatment monitoring and treatment allocation | NIH | National Cancer Institute | 2021 to 2025 | $3,120,699 | May 1, 2021 | April 30, 2027 | GEVAERT, OLIVIER | reporter.nih.gov |
| PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors) | NIH | National Cancer Institute | 2024 to 2025 | $3,108,431 | May 1, 2024 | April 30, 2026 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Virtual Biopsy with Tissue-level Accuracy in Glioma | NIH | National Cancer Institute | 2021 to 2025 | $3,099,979 | April 15, 2021 | March 31, 2027 | MALDJIAN, JOSEPH A | reporter.nih.gov |
| Focused ultrasound-enabled brain tumor liquid biopsy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $3,097,242 | June 1, 2024 | March 31, 2028 | CHEN, HONG | reporter.nih.gov |
| Advancing Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning | NIH | National Cancer Institute | 2021 to 2025 | $3,063,698 | January 17, 2017 | June 30, 2027 | LEUTHARDT, ERIC CLAUDE | reporter.nih.gov |
| Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,062,772 | September 22, 2021 | August 31, 2026 | MUNN, LANCE L. | reporter.nih.gov |
| Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,009,508 | February 1, 2021 | January 31, 2027 | ANDRONESI, OVIDIU C | reporter.nih.gov |
| DCTD Cancer Imaging | NIH | National Cancer Institute | 2021 to 2024 | $3,009,076 | September 26, 2008 | August 30, 2019 | HEIMBROOK, DAVID | reporter.nih.gov |
| Systems biology of intratumoral heterogeneity in glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,962,426 | January 1, 2022 | December 31, 2026 | BALIGA, NITIN S | reporter.nih.gov |
| Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,945,301 | August 1, 2021 | June 30, 2027 | LI, SHULIN | reporter.nih.gov |
| Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $2,929,456 | August 1, 2020 | April 30, 2026 | BROWN, CHRISTINE | reporter.nih.gov |
| Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,926,627 | January 1, 2018 | November 30, 2025 | MELLINGHOFF, INGO K | reporter.nih.gov |
| Quantitative Glioblastoma Margin and Infiltration Mapping with Advanced Diffusion-Relaxation MRI | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,908,680 | August 15, 2022 | May 31, 2027 | WESTIN, CARL-FREDRIK | reporter.nih.gov |
| Optical Analogs to MRI Contrast Agents for Surgical Guidance of Brain Tumor Resection | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,877,679 | February 1, 2021 | November 30, 2026 | DAVIS, SCOTT C | reporter.nih.gov |
| Advancing molecular fluorescence-guided surgery platform | NIH | National Cancer Institute | 2021 to 2025 | $2,872,577 | April 8, 2013 | March 31, 2027 | PAULSEN, KEITH D. | reporter.nih.gov |
| Lentiviral-Induced Swine Model of Spinal Cord Glioma | NIH | National Cancer Institute | 2021 to 2025 | $2,866,663 | June 1, 2021 | May 31, 2026 | BOULIS, NICHOLAS M | reporter.nih.gov |
| A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,862,121 | September 1, 2021 | June 30, 2026 | KURMASHEVA, RAUSHAN | reporter.nih.gov |
| New methods to measure and interrupt metabolic fluxes in brain cancer | NIH | National Cancer Institute | 2025 | $2,820,337 | August 6, 2025 | July 31, 2029 | WAHL, DANIEL R | reporter.nih.gov |
| Inducing Neural Maturation in Medulloblastoma by Targeting EZH2 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,801,562 | September 15, 2022 | August 31, 2026 | SNUDERL, MATIJA | reporter.nih.gov |
| Clinical Translation of Stimulated Raman Histology | NIH | National Cancer Institute | 2021 to 2025 | $2,796,242 | August 1, 2018 | July 31, 2027 | ORRINGER, DANIEL | reporter.nih.gov |
| Defining the role of cytomegalovirus in glioblastoma therapies | NIH | National Cancer Institute | 2022 to 2025 | $2,785,152 | April 11, 2022 | March 31, 2027 | LAWLER, SEAN EDWARD | reporter.nih.gov |
| Next Generation GPC2-CARs for Medulloblastoma | NIH | National Cancer Institute | 2024 to 2025 | $2,781,440 | September 13, 2024 | August 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $2,760,954 | March 1, 2021 | February 28, 2026 | WAHL, DANIEL R | reporter.nih.gov |
| Deciphering heritability, plasticity and differentiation trajectories in gliomas via single-cell multi-omics | NIH | National Cancer Institute | 2021 to 2025 | $2,757,093 | April 5, 2021 | March 31, 2026 | SUVA, MARIO LUCA | reporter.nih.gov |
| Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,752,745 | March 8, 2021 | February 28, 2026 | BURMA, SANDEEP | reporter.nih.gov |
| Image-guided combination therapies for radiotherapy-induced neurocognitive impairment in pediatric brain tumor survivors | NIH | National Cancer Institute | 2021 to 2025 | $2,750,972 | July 12, 2021 | June 30, 2027 | NGEN, ETHEL JOSO | reporter.nih.gov |
| Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors | NIH | National Cancer Institute | 2023 to 2025 | $2,739,146 | August 1, 2023 | July 31, 2030 | MILLER, JEFFREY S. | reporter.nih.gov |
| Understanding druggable drivers of meningioma tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,733,596 | August 1, 2021 | July 31, 2026 | RALEIGH, DAVID R | reporter.nih.gov |
| Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,726,662 | April 4, 2011 | August 31, 2027 | WECHSLER-REYA, ROBERT J. | reporter.nih.gov |
| Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma | NIH | National Cancer Institute | 2023 to 2025 | $2,724,833 | August 1, 2023 | July 31, 2028 | OLSON, JAMES M | reporter.nih.gov |
| Identifying therapeutic pathways targeting medulloblastoma-immune cell interactions | NIH | National Cancer Institute | 2021 to 2025 | $2,721,281 | May 1, 2021 | April 30, 2027 | FRAENKEL, ERNEST | reporter.nih.gov |
| Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122 | NIH | National Cancer Institute | 2022 to 2025 | $2,699,777 | February 15, 2022 | December 31, 2026 | HAFLER, DAVID A. | reporter.nih.gov |
| Utility of memantine in preventing cognitive dysfunction in children receiving cranial radiotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,688,046 | September 18, 2019 | December 31, 2026 | LAACK, NADIA N | reporter.nih.gov |
| How the 3D Architecture of the Brain Shapes Cancer Cell Fate Decisions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,670,000 | September 30, 2021 | August 31, 2026 | FILBIN, MARIELLA GRUBER | reporter.nih.gov |
| Targeting platinum(IV) prodrug to GBM tumors using a brevican-binding peptide | NIH | National Cancer Institute | 2022 to 2025 | $2,666,597 | September 1, 2022 | August 31, 2026 | CHO, CHOI-FONG | reporter.nih.gov |
| MT-125 for the Therapeutic Treatment of Glioblastoma | NIH | National Cancer Institute | 2023 to 2025 | $2,666,500 | April 1, 2023 | December 31, 2025 | ROSENFELD, STEVEN S | reporter.nih.gov |
| Training Program in Translational Brain Tumor Research | NIH | National Cancer Institute | 2021 to 2025 | $2,658,559 | September 1, 2010 | August 31, 2030 | COSTELLO, JOSEPH F | reporter.nih.gov |
| Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,644,746 | August 1, 2022 | July 31, 2027 | WEISS, WILLIAM A | reporter.nih.gov |
| Mechanisms of Hedgehog signaling in glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $2,642,438 | July 1, 2021 | April 30, 2026 | RALEIGH, DAVID R | reporter.nih.gov |
| Synthetic lethalities to cell cycle disruption in glioma | NIH | National Cancer Institute | 2022 to 2025 | $2,642,252 | May 13, 2022 | April 30, 2027 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| Generalizable quantitative imaging and machine learning signatures in glioblastoma, for precision diagnostics and personalized treatment: the ReSPOND consortium | NIH | National Cancer Institute | 2022 to 2025 | $2,631,857 | June 1, 2022 | May 31, 2027 | DAVATZIKOS, CHRISTOS | reporter.nih.gov |
| Biogenic Gas Nanostructures as Molecular Imaging Reporters for Ultrasound | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,631,696 | January 1, 2024 | December 31, 2027 | SHAPIRO, MIKHAIL | reporter.nih.gov |
| New treatment monitoring biomarkers for brain tumors using multiparametric MRI with machine learning | NIH | National Cancer Institute | 2021 to 2025 | $2,626,982 | April 15, 2021 | March 31, 2027 | SCHMAINDA, KATHLEEN MARIE | reporter.nih.gov |
| Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas | NIH | National Cancer Institute | 2021 to 2025 | $2,618,523 | February 1, 2021 | January 31, 2026 | SAYOUR, ELIAS | reporter.nih.gov |
| Visualizing oxidative stress using hyperpolarized magnetic resonance | NIH | National Cancer Institute | 2021 to 2024 | $2,607,387 | June 1, 2020 | May 31, 2026 | KESHARI, KAYVAN R | reporter.nih.gov |
| Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and Immunogenomics | NIH | National Cancer Institute | 2022 to 2025 | $2,607,031 | September 1, 2022 | August 31, 2026 | FRANCIS, STEPHEN STARKO | reporter.nih.gov |
| Quantitative Steady-State and Dynamic Metabolic MRI for Evaluating Patients with Glioma | NIH | National Cancer Institute | 2022 to 2025 | $2,598,382 | March 8, 2022 | February 28, 2027 | XU, DUAN | reporter.nih.gov |
| Development of multinuclear MRI for image guided therapy of glioma patients | NIH | National Cancer Institute | 2021 to 2025 | $2,587,679 | July 1, 2023 | June 30, 2028 | ANDRONESI, OVIDIU C | reporter.nih.gov |
| Novel nano-vaccine technology for inducing immunity against gliomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,581,798 | July 15, 2021 | June 30, 2026 | MOON, JAMES J. | reporter.nih.gov |
| Systematic Characterization and Targeting of Neomorphic Drivers in Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,554,135 | September 19, 2023 | August 31, 2028 | MILLS, GORDON B. | reporter.nih.gov |
| Discovery, Biology and Risk of Inherited Variants in Glioma | NIH | National Cancer Institute | 2021 to 2024 | $2,549,276 | April 10, 2020 | April 30, 2026 | BONDY, MELISSA L. | reporter.nih.gov |
| Mechanisms Controlling Sensitivity and Resistance to Dioxin-like Compounds: Role of AIP | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,546,882 | September 7, 2022 | August 31, 2027 | HAHN, MARK E | reporter.nih.gov |
| CDKN2A couples lipid metabolism to ferroptosis in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,535,633 | April 1, 2021 | January 31, 2026 | NATHANSON, DAVID A. | reporter.nih.gov |
| Neuronal Regulation of Low-Grade Gliomagenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,518,768 | April 1, 2022 | March 31, 2027 | MONJE-DEISSEROTH, MICHELLE | reporter.nih.gov |
| NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,512,290 | September 1, 2020 | May 31, 2026 | RAMESH, VIJAYA | reporter.nih.gov |
| Focused ultrasound-mediated intranasal brain drug delivery technique (FUSIN) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,511,680 | April 1, 2019 | April 30, 2027 | CHEN, HONG | reporter.nih.gov |
| IMAGING TELOMERE MAINTENANCE MECHANISMS IN GLIOMAS | NIH | National Cancer Institute | 2021 to 2024 | $2,509,037 | February 11, 2020 | January 31, 2026 | VISWANATH, PAVITHRA | reporter.nih.gov |
| Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,499,820 | September 9, 2022 | August 31, 2028 | WANG, XIULI | reporter.nih.gov |
| Social Connectedness in Pediatric Brain Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,482,532 | January 1, 2022 | June 30, 2027 | HOCKING, MATTHEW C. | reporter.nih.gov |
| Epigenetics and 3D Structure of miR-10b/HoxD Locus in the Brain and Malignant Glioma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,479,682 | September 15, 2020 | July 31, 2025 | KRICHEVSKY, ANNA M. | reporter.nih.gov |
| Diagnosis of indeterminate brain lesions using MRI-based machine learning and polygenic risk models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,473,627 | August 15, 2020 | December 31, 2025 | ECKEL PASSOW, JEANETTE E | reporter.nih.gov |
| Multi-receptor Targeting of Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $2,470,493 | September 15, 2021 | August 31, 2026 | DEBINSKI, WALDEMAR | reporter.nih.gov |
| Targeting Myeloid Metabolism to Reprogram the Tumor Microenvironment of Glioblastoma | NIH | National Cancer Institute | 2025 | $2,467,799 | August 18, 2025 | July 31, 2029 | STEGH, ALEXANDER H. | reporter.nih.gov |
| Imaging signatures of genetic mutations in glioblastoma using machine learning | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,467,136 | June 1, 2002 | November 30, 2025 | DAVATZIKOS, CHRISTOS | reporter.nih.gov |
| Determining the role of lipid droplets and their therapeutic potential in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,447,960 | September 15, 2018 | June 30, 2028 | GUO, DELIANG | reporter.nih.gov |
| Magnetofluorescent nanoplatform for glioblastoma therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,444,078 | September 11, 2020 | August 31, 2025 | YU, JOHN S | reporter.nih.gov |
| A “STICK” theranostic nanoplatform for image-guided drug delivery to brain malignancies | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,441,420 | December 18, 2015 | May 31, 2026 | LI, YUANPEI | reporter.nih.gov |
| Improved whole-brain spectroscopic MRI for radiation therapy planning | NIH | National Cancer Institute | 2022 to 2025 | $2,436,201 | May 5, 2022 | April 30, 2027 | SHIM, HYUNSUK | reporter.nih.gov |
| Label-free fluorescence lifetime imaging for intraoperative real-time guidance of neurological procedures | NIH | National Cancer Institute | 2021 to 2025 | $2,434,599 | December 15, 2020 | November 30, 2026 | MARCU, LAURA | reporter.nih.gov |
| Imaging and Liquid Biopsy for Glioma Diagnosis and Treatment Monitoring | NIH | National Cancer Institute | 2021 to 2024 | $2,433,883 | March 1, 2020 | August 31, 2025 | BALAJ, LEONORA | reporter.nih.gov |
| Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,423,705 | April 1, 2022 | March 31, 2027 | ELLINGSON, BENJAMIN M. | reporter.nih.gov |
| Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology | NIH | National Cancer Institute | 2023 to 2025 | $2,416,050 | September 7, 2023 | August 31, 2028 | CHI, HONGBO | reporter.nih.gov |
| Drivers of metabolic plasticity promote radiation resistance in glioblastoma multiforme | NIH | National Cancer Institute | 2021 to 2024 | $2,410,628 | July 6, 2020 | June 30, 2026 | VLASHI, ERINA | reporter.nih.gov |
| Imaging and Targeted Auger Radiotherapy of High-Grade Glioma | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,407,488 | May 1, 2020 | January 31, 2025 | GARBOW, JOEL RICHARD | reporter.nih.gov |
| Tumor-Selective Delivery Approaches for Medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,405,248 | March 15, 2020 | December 31, 2024 | HELLER, DANIEL ALAN | reporter.nih.gov |
| Credentialing next-generation human glioma models for precision therapeutics | NIH | National Cancer Institute | 2022 to 2025 | $2,403,397 | January 12, 2022 | December 31, 2026 | MILLER, CHRISTOPHER RYAN | reporter.nih.gov |
| Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas | NIH | National Cancer Institute | 2022 to 2024 | $2,400,000 | September 1, 2022 | December 31, 2024 | VOVIS, GERALD FRANCIS | reporter.nih.gov |
| Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM) | NIH | National Cancer Institute | 2023 to 2025 | $2,400,000 | August 8, 2023 | July 31, 2026 | NAGY, JON OWEN | reporter.nih.gov |
| Contribution of Myeloid-Derived Suppressor Cells to Neuro-Inflammatory Alterations and Disease Progression in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,398,824 | May 1, 2022 | April 30, 2030 | LATHIA, JUSTIN D. | reporter.nih.gov |
| Tumor Monorail Device for Serial Glioblastoma Biopsy | NIH | National Cancer Institute | 2023 to 2025 | $2,397,615 | August 1, 2023 | August 31, 2026 | MEEHAN, SEAN | reporter.nih.gov |
| Glioma Circuitry: Bridging Systems Neuroscience and Cancer | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $2,374,452 | September 30, 2018 | June 30, 2024 | MONJE-DEISSEROTH, MICHELLE | reporter.nih.gov |
| Standardized Molecular Analyses of Glioma EVs | NIH | National Cancer Institute | 2021 to 2024 | $2,363,088 | July 1, 2020 | June 30, 2025 | CARTER, BOB S | reporter.nih.gov |
| Targeting integrated metabolic and epigenetic pathways in childhood ependymomas | NIH | National Cancer Institute | 2022 to 2025 | $2,359,774 | July 5, 2022 | June 30, 2027 | VENNETI, SRIRAM | reporter.nih.gov |
| T Cell Regulation of Low-Grade Glioma | NIH | National Cancer Institute | 2022 to 2025 | $2,353,237 | September 9, 2022 | August 31, 2027 | GUTMANN, DAVID H | reporter.nih.gov |
| One-shot morphologic, hemodynamic and metabolic MR imaging of brain tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,348,772 | July 5, 2021 | June 30, 2027 | KODIBAGKAR, VIKRAM D. | reporter.nih.gov |
| Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,344,893 | April 1, 2021 | December 31, 2025 | PRICE, RICHARD J. | reporter.nih.gov |
| Tumor-associated macrophages in vasogenic cerebral edema in brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,339,629 | September 30, 2017 | August 31, 2027 | HAMBARDZUMYAN, DOLORES | reporter.nih.gov |
| Chromatin Dynamics and Genome Regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,335,578 | August 4, 2017 | May 31, 2027 | BANASZYNSKI, LAURA | reporter.nih.gov |
| Immuno-Cell Therapy for Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,328,113 | January 1, 2022 | December 31, 2026 | BREAKEFIELD, XANDRA OWENS | reporter.nih.gov |
| Metabolic Regulation of Glioblastoma Epitranscriptomics | NIH | National Cancer Institute | 2022 to 2025 | $2,327,158 | July 7, 2022 | June 30, 2027 | AGNIHOTRI, SAMEER | reporter.nih.gov |
| TRANSCRANIAL FUS THERAPY WITH CLOSED-LOOP US IMAGE GUIDANCE AND CIRCULATING | NIH | National Cancer Institute | 2021 to 2025 | $2,322,901 | August 1, 2020 | April 30, 2027 | ARVANITIS, KONSTANTINOS-COSTAS | reporter.nih.gov |
| Glial immune signaling in radiation-induced brain injury | NIH | National Cancer Institute | 2021 to 2025 | $2,293,007 | September 1, 2021 | August 31, 2026 | ACHARYA, MUNJAL M | reporter.nih.gov |
| Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,291,623 | September 20, 2019 | May 31, 2030 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| DeepSRH: Transforming Molecular Cancer Screening with Stimulated Raman Histology and Deep Neural Networks | NIH | National Cancer Institute | 2025 | $2,284,054 | September 1, 2025 | August 31, 2029 | HOLLON, TODD CHARLES | reporter.nih.gov |
| Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade Gliomas | NIH | National Cancer Institute | 2021 to 2024 | $2,283,773 | December 11, 2017 | February 28, 2026 | RAO, ARVIND | reporter.nih.gov |
| Single Cell Analysis of the Infiltrative Margins of Glioblastoma and Post Treatment Recurrence | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,280,885 | July 1, 2017 | April 30, 2028 | BRUCE, JEFFREY N | reporter.nih.gov |
| Targeting Go and Grow in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,271,628 | September 1, 2020 | June 30, 2025 | ROSENFELD, STEVEN S | reporter.nih.gov |
| Determining the optimal ion and fractionation scheme for the treatment of GBM in a comprehensive human organoid model | NIH | National Cancer Institute | 2021 to 2025 | $2,268,156 | March 1, 2021 | February 28, 2026 | GROSSHANS, DAVID R | reporter.nih.gov |
| Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma. | NIH | National Cancer Institute | 2022 to 2025 | $2,256,713 | September 23, 2022 | August 31, 2027 | STEGH, ALEXANDER H. | reporter.nih.gov |
| Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas | NIH | National Cancer Institute | 2025 | $2,245,802 | April 1, 2023 | July 31, 2027 | BROWNSTEIN, MICHAEL J | reporter.nih.gov |
| 3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformation | NIH | National Cancer Institute | 2021 to 2024 | $2,235,130 | July 1, 2020 | June 30, 2025 | COSTELLO, JOSEPH F | reporter.nih.gov |
| PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors | NIH | National Cancer Institute | 2024 to 2025 | $2,221,836 | May 1, 2024 | April 30, 2026 | GRAY, NATHANAEL SCHIANDER | reporter.nih.gov |
| Fluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive Glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,215,107 | August 1, 2022 | July 31, 2027 | SIMBERG, DMITRI | reporter.nih.gov |
| Improving genetically engineered T cells for medulloblastomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,210,532 | April 15, 2021 | April 30, 2026 | KRENCIUTE, GIEDRE | reporter.nih.gov |
| Improving pediatric brain tumor treatments using FLASH radiotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,200,868 | July 1, 2021 | June 30, 2027 | LIMOLI, CHARLES | reporter.nih.gov |
| Plexin-B2 Function in Glioma Invasion | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,200,420 | April 1, 2016 | June 30, 2026 | FRIEDEL, ROLAND HORST | reporter.nih.gov |
| Connectivity mapping identified novel combination therapy for glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,198,374 | September 1, 2025 | August 31, 2027 | SHONKA, NICOLE | reporter.nih.gov |
| In vivo dual-axis confocal microscopy of 5-ALA-induced PpIX to guide low-grade glioma resections | NIH | National Cancer Institute | 2021 to 2024 | $2,180,105 | June 1, 2020 | May 31, 2026 | LIU, JONATHAN T.C. | reporter.nih.gov |
| RaceCAR-M immunotherapy for cancer and beyond | NIH | National Cancer Institute | 2024 to 2025 | $2,177,000 | September 20, 2024 | August 31, 2029 | MONTELL, DENISE J. | reporter.nih.gov |
| Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,171,748 | June 15, 2021 | April 30, 2026 | JIANG, WEN | reporter.nih.gov |
| lncRNA regulation of glioblastoma progression and therapeutic resistance | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,168,484 | December 1, 2021 | November 30, 2026 | YU, JENNIFER S | reporter.nih.gov |
| S100A4 mediated immune suppression in GBM | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,162,990 | April 1, 2021 | December 31, 2026 | YUN, KYUSON | reporter.nih.gov |
| Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress | NIH | National Cancer Institute | 2021 to 2022 | $2,160,078 | September 17, 2018 | August 31, 2024 | WILLEY, CHRISTOPHER D | reporter.nih.gov |
| Using implantable microdevices for deep phenotyping of multiple drug responses in brain tumor patients | NIH | National Cancer Institute | 2023 to 2025 | $2,144,670 | August 1, 2023 | July 31, 2028 | JONAS, OLIVER | reporter.nih.gov |
| Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,142,892 | March 15, 2022 | February 28, 2027 | LAHANN, JOERG | reporter.nih.gov |
| Gene Edited and Engineered Tumor Cell Therapeutics for Cancer | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,135,976 | April 15, 2021 | March 31, 2026 | SHAH, KHALID A | reporter.nih.gov |
| Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in Glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $2,135,258 | June 30, 2022 | May 31, 2028 | TIWARI, PALLAVI | reporter.nih.gov |
| Use of CTEP portfolio compounds to counteract phenotype conversion in GBM | NIH | National Cancer Institute | 2022 to 2025 | $2,134,457 | January 1, 2022 | December 31, 2026 | PAJONK, FRANK | reporter.nih.gov |
| Quantitative MRI for Pediatric Optic Pathway Glioma Treatment Response | NIH | National Cancer Institute | 2022 to 2024 | $2,119,273 | June 17, 2020 | July 31, 2025 | AVERY, ROBERT ANDREW | reporter.nih.gov |
| STAG2 mutations and 3D genome organization in glioblastoma multiforme | NIH | National Cancer Institute | 2022 to 2025 | $2,118,300 | August 10, 2022 | July 31, 2027 | WALDMAN, TODD A | reporter.nih.gov |
| Continuous, Non-Invasive Optical Monitoring of Circulating Tumor Cell-Mediated Metastasis in Awake Mice | NIH | National Cancer Institute | 2022 to 2025 | $2,117,767 | March 3, 2022 | February 28, 2027 | NIEDRE, MARK JONATHAN | reporter.nih.gov |
| Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers | NIH | National Cancer Institute | 2021 to 2023 | $2,114,438 | May 15, 2018 | November 30, 2024 | DUCKETT, DEREK RONALD | reporter.nih.gov |
| Engineered antibody fragments for PET imaging of immunotherapeutic targets in gliomas | NIH | National Cancer Institute | 2021 to 2024 | $2,112,345 | July 15, 2020 | June 30, 2026 | KOHANBASH, GARY | reporter.nih.gov |
| Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,109,872 | September 15, 2019 | February 28, 2029 | CHIOCCA, E. ANTONIO | reporter.nih.gov |
| The role of Myeloid cells in pediatric-high grade gliomas | NIH | National Cancer Institute | 2022 to 2025 | $2,100,261 | June 1, 2022 | June 30, 2025 | HAMBARDZUMYAN, DOLORES | reporter.nih.gov |
| Mapping the Cerebellar Origins of Medulloblastoma Subgroups | NIH | National Cancer Institute | 2023 to 2025 | $2,099,734 | February 16, 2023 | January 31, 2028 | NORTHCOTT, PAUL | reporter.nih.gov |
| Uncovering exRNA and protein determinants of secreted vesicle heterogeneity by flow cytometric purification of vesicle subsets from cells and plasma | NIH | National Cancer Institute | 2021 to 2022 | $2,099,368 | July 15, 2019 | August 31, 2024 | COFFEY, ROBERT J. | reporter.nih.gov |
| A First-in-Class Therapeutic Antibody for Treatment of Acromegaly | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $2,095,403 | September 5, 2024 | July 31, 2027 | ZANGHI, ADIBA | reporter.nih.gov |
| Characterizing cytotoxic therapy induced shifts in the cost-to-benefit ratio of high ploidy | NIH | National Cancer Institute | 2022 to 2025 | $2,095,115 | September 1, 2022 | August 31, 2027 | ANDOR, NOEMI | reporter.nih.gov |
| Naturalistic Neuroimaging for Presurgical Language Mapping | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2025 | $2,094,936 | April 1, 2023 | February 29, 2028 | TIE, YANMEI | reporter.nih.gov |
| Developing a Translation Pipeline for VHL Mutant Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $2,084,051 | April 1, 2019 | March 31, 2028 | MCDERMOTT, DAVID | reporter.nih.gov |
| Ex vivo analysis of human brain tumor cells in a microvascular niche model | NIH | National Cancer Institute | 2021 to 2024 | $2,082,785 | February 4, 2020 | January 31, 2025 | FAN, RONG | reporter.nih.gov |
| Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition | NIH | National Cancer Institute | 2023 to 2025 | $2,082,285 | July 3, 2023 | June 30, 2028 | AMANKULOR, NDUKA MGBECHINYERE | reporter.nih.gov |
| Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662) | NIH | National Cancer Institute | 2021 to 2024 | $2,081,567 | July 1, 2021 | November 30, 2024 | RICH, JEREMY N | reporter.nih.gov |
| Cellular Plasticity and equilibrium in GBM Progression | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,075,893 | April 1, 2017 | May 31, 2027 | AHMED, ATIQUE U. | reporter.nih.gov |
| Role of FACT in ZFTA-RelA fusion driven ependymoma | NIH | National Cancer Institute | 2023 to 2025 | $2,070,282 | April 1, 2023 | March 31, 2028 | VENERE, MONICA | reporter.nih.gov |
| Molecular Mechanisms of TRAF7 Mutant Aggressive Meningiomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,062,866 | July 1, 2020 | April 30, 2026 | GUNEL, MURAT | reporter.nih.gov |
| Understanding EGF receptor activation by growth factors and oncogenic mutations | NIH | National Cancer Institute | 2021 to 2024 | $2,059,926 | August 18, 2015 | April 30, 2026 | LEMMON, MARK A | reporter.nih.gov |
| Leveraging Zika virus and the immune system to treat glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,059,300 | December 1, 2020 | November 30, 2025 | CHHEDA, MILAN GIRISH | reporter.nih.gov |
| Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma | NIH | National Cancer Institute | 2023 to 2025 | $2,052,826 | September 7, 2023 | August 31, 2028 | MACK, STEPHEN C | reporter.nih.gov |
| Selectivity and regulation of mRNA demethylation by iron-dependent dioxygenases | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,051,539 | August 1, 2021 | May 31, 2027 | MUGRIDGE, JEFFREY SCOTT | reporter.nih.gov |
| Exploiting cell fate transition to overcome radiation resistance in glioblastoma | NIH | National Cancer Institute | 2023 to 2025 | $2,038,414 | July 28, 2023 | June 30, 2028 | SULMAN, ERIK | reporter.nih.gov |
| Mapping Immune Contexture and Crosstalk with Tumor Cells At GBM Margin | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,037,377 | September 9, 2023 | August 31, 2028 | ZOU, HONGYAN JENNY | reporter.nih.gov |
| Ultrasound based neurosurgical navigation with uncertainty visualization | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,033,410 | June 2, 2022 | February 28, 2027 | WELLS, WILLIAM M. | reporter.nih.gov |
| Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors | NIH | National Cancer Institute | 2023 to 2025 | $2,025,823 | September 19, 2023 | August 31, 2028 | SUVA, MARIO LUCA | reporter.nih.gov |
| Development of a prototype clinical theranostic platform combining Magnetic Particle Imaging (MPI) and Magnetic Fluid Hyperthermia (MFH) for the treatment of brain tumors | NIH | National Cancer Institute | 2023 to 2024 | $2,023,904 | July 1, 2023 | June 30, 2025 | GOODWILL, PATRICK | reporter.nih.gov |
| Development of an innovative neurosurgical planning tool for awake craniotomy | NIH | National Institute of Mental Health | 2023 to 2025 | $2,023,086 | April 1, 2025 | March 31, 2026 | SIMS, MAXWELL HARRISON | reporter.nih.gov |
| Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma | NIH | National Cancer Institute | 2021 to 2025 | $2,016,077 | February 1, 2021 | January 31, 2027 | HATLEY, MARK EDWARD | reporter.nih.gov |
| Molecular determinants of cellular heterogeneity and therapeutic resistance in GBM. | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,014,849 | April 15, 2021 | January 31, 2026 | LOPEZ-BERTONI, HERNANDO MARTIN | reporter.nih.gov |
| Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,006,629 | January 15, 2022 | December 31, 2026 | CASTRO, MARIA G | reporter.nih.gov |
| High-resolution Infrared Thermal Imaging (ITI) for Simultaneous Functional Mapping of the Entire Craniotomy in Awake Patients | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,005,048 | December 1, 2020 | November 30, 2025 | PARRISH, TODD B | reporter.nih.gov |
| Matching panels of in vivo and in vitro model system of pediatric brain tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,001,657 | March 3, 2020 | February 28, 2026 | LI, XIAONAN | reporter.nih.gov |
| BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas | NIH | National Cancer Institute | 2021 to 2022 | $2,001,625 | September 18, 2015 | May 31, 2023 | CRAPO, JAMES D | reporter.nih.gov |
| Synergistic microglial activation and tumor cell killing for improved GBM response | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,000,425 | January 15, 2021 | December 31, 2025 | CHANDRAMOHAN, VIDYALAKSHMI | reporter.nih.gov |
| Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | May 1, 2022 | August 31, 2024 | MARCUS, STUART | reporter.nih.gov |
| Topic #402: Artificial Intelligence-Aided Imaging for Cancer Prevention, Diagnosis, and MonitoringProject Title: An Interpretable Physician-In-The-Loop Al-Aided Software For Tumor Surveillance In Br | NIH | National Cancer Institute | 2022 | $2,000,000 | September 15, 2022 | September 14, 2024 | RAHAL, HAYAT | reporter.nih.gov |
| A multicenter study in bronchoscopy combining Stimulated Raman Histology with Artificial intelligence for rapid lung cancer detection - The ON-SITE study | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | March 1, 2023 | February 28, 2026 | FREUDIGER, CHRISTIAN | reporter.nih.gov |
| A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma | NIH | National Cancer Institute | 2022 to 2023 | $1,999,998 | September 16, 2022 | June 30, 2024 | REILLY, LAURENCE | reporter.nih.gov |
| GENETICALLY ENGINEERED T CELLS FOR DIPG | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,999,395 | August 1, 2022 | July 31, 2027 | KRENCIUTE, GIEDRE | reporter.nih.gov |
| TOPIC 382 - INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW | NIH | National Cancer Institute | 2021 | $1,997,803 | January 22, 2021 | January 21, 2023 | GEBHART, STEVE | reporter.nih.gov |
| Interstitial Fluid Flow Regulates Glioma Cell Invasion | NIH | National Cancer Institute | 2021 to 2024 | $1,997,774 | December 1, 2022 | November 30, 2024 | MUNSON, JENNIFER M | reporter.nih.gov |
| Spatial genomics analysis of tumor samples | NIH | National Cancer Institute | 2023 to 2024 | $1,996,962 | September 1, 2023 | August 31, 2025 | FRIEDA, KIRSTEN | reporter.nih.gov |
| Calcium Channels in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,996,730 | September 21, 2022 | August 31, 2027 | ABOUNADER, ROGER | reporter.nih.gov |
| Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,996,509 | July 1, 2023 | June 30, 2028 | JIANG, SHANSHAN | reporter.nih.gov |
| Transporters and Medulloblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,995,922 | April 1, 2015 | November 30, 2026 | SCHUETZ, JOHN D | reporter.nih.gov |
| Biomarkers of Vision Loss in Children with Optic Pathway Gliomas | NIH | National Eye Institute | 2021 to 2023 | $1,991,559 | March 1, 2019 | February 28, 2025 | AVERY, ROBERT ANDREW | reporter.nih.gov |
| Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,990,713 | September 25, 2023 | August 31, 2026 | YU, GUOQIANG | reporter.nih.gov |
| Targeting vulnerabilities of PPM1D-mutant gliomas | NIH | National Cancer Institute | 2021 to 2025 | $1,989,782 | February 1, 2021 | January 31, 2026 | BANDOPADHAYAY, PRATITI | reporter.nih.gov |
| Optimization of ultrasound-mediated drug delivery to the brain under clinically relevant conditions | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,985,374 | September 12, 2022 | June 30, 2026 | MCDANNOLD, NATHAN J. | reporter.nih.gov |
| Modeling the Glioblastoma Microenvironment to Uncover Progression Mechanisms and Therapeutic Targets | NIH | National Cancer Institute | 2021 to 2024 | $1,980,275 | May 1, 2020 | April 30, 2026 | BRAT, DANIEL J | reporter.nih.gov |
| Isocitrate dehydrogenase (IDH) mutations as drivers of organelle stress and dysfunction | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,977,856 | August 1, 2020 | June 30, 2030 | SOHL, CHRISTAL DYANE | reporter.nih.gov |
| New Therapeutic Approaches for Stratified High-REST GBM Subtype | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,972,350 | December 1, 2021 | November 30, 2026 | MAJUMDER, SADHAN | reporter.nih.gov |
| Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,972,350 | April 15, 2021 | February 28, 2027 | CHEN, YIWEN | reporter.nih.gov |
| HDAC Inhibitors Reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,972,350 | April 1, 2021 | March 31, 2026 | SIEGELIN, MARKUS D | reporter.nih.gov |
| Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | NIH | National Cancer Institute | 2021 to 2025 | $1,970,730 | February 1, 2021 | January 31, 2027 | FUEYO, JUAN | reporter.nih.gov |
| Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2 | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,964,651 | May 1, 2021 | February 28, 2027 | FUKUMURA, DAI | reporter.nih.gov |
| Defining transcriptional networks and chromatin conformations regulating glioma tumorigenesis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,963,150 | June 15, 2021 | March 31, 2026 | GLASGOW, STACEY MARIE | reporter.nih.gov |
| Sialylation in the Maintenance and Metabolic Plasticity of Neural Stem Cell-Like Brain Tumor Cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,962,163 | August 15, 2022 | July 31, 2027 | HJELMELAND, ANITA BORTON | reporter.nih.gov |
| MRI-Compatible Robot for Real-Time Image-Guided Stereotactic Neurosurgical Procedures: A Novel Platform Technology | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,961,701 | September 20, 2021 | June 30, 2025 | MONFAREDI, REZA | reporter.nih.gov |
| The Role of Collagen and its Signaling Mechanisms in Glioma Progression and Invasion. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,960,669 | December 15, 2021 | November 30, 2026 | LOWENSTEIN, PEDRO R. | reporter.nih.gov |
| Therapeutic resistance and aggressive malignancy in glioblastomas: the contribution of GTP metabolism through regulation by IMPDH2 | NIH | National Cancer Institute | 2021 to 2025 | $1,959,151 | July 7, 2021 | June 30, 2027 | SASAKI, ATSUO | reporter.nih.gov |
| Neoadjuvant checkpoint blockade for recurrent glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,955,108 | August 1, 2022 | April 30, 2027 | PRINS, ROBERT M | reporter.nih.gov |
| Inhibition of wild-type IDH1 as a ferroptosis-inducing therapeutic approach for the treatment of malignant glioma. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,952,697 | September 1, 2022 | June 30, 2027 | STEGH, ALEXANDER H. | reporter.nih.gov |
| Shared mechanisms of astrocyte maturation in development and glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,949,981 | September 30, 2021 | June 30, 2027 | SPANGLE, JENNIFER MARIE | reporter.nih.gov |
| Overcoming Resistance Mechanisms in Hedgehog and Myc-amplified Medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,949,505 | December 1, 2020 | November 30, 2025 | MAHATO, RAM I. | reporter.nih.gov |
| First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development | NIH | National Cancer Institute | 2021 to 2022 | $1,948,791 | September 1, 2021 | August 31, 2024 | KRISHNAN, RAJESH | reporter.nih.gov |
| Targeting RNA Splicing in Glioma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,947,555 | July 1, 2022 | April 30, 2027 | CHENG, SHI-YUAN | reporter.nih.gov |
| Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking | NIH | National Cancer Institute | 2023 to 2025 | $1,946,230 | September 21, 2023 | August 31, 2027 | ROYBAL, KOLE T | reporter.nih.gov |
| Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,945,914 | April 1, 2021 | August 31, 2026 | BALYASNIKOVA, IRINA V | reporter.nih.gov |
| Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma | NIH | National Cancer Institute | 2021 to 2024 | $1,945,311 | January 1, 2019 | December 31, 2025 | BROWN, CHRISTINE | reporter.nih.gov |
| OCT as a Platform for Non-Invasive Virtual H&E Biopsy | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $1,944,467 | September 15, 2021 | August 31, 2027 | WINETRAUB, YONATAN | reporter.nih.gov |
| Targeting AVIL in Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,941,611 | March 1, 2020 | February 28, 2026 | LI, HUI | reporter.nih.gov |
| A Physiologic Adaptive Radiation Therapy Pipeline for Glioblastoma by Daily Multiparametric MRI and Machine Learning | NIH | National Cancer Institute | 2022 to 2025 | $1,941,434 | March 3, 2022 | August 1, 2025 | MELLON, ERIC ALBERT | reporter.nih.gov |
| Endothelial plasticity in glioma vascularization and therapy resistance | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,941,218 | September 30, 2015 | November 30, 2025 | FAN, YI | reporter.nih.gov |
| Fluorescence Guided Surgery using Near Infrared Nerve-specific Probes for Cranial Nerve Preservation | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,940,971 | December 1, 2022 | November 30, 2027 | GIBBS, SUMMER LYNNE | reporter.nih.gov |
| Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments. | NIH | National Cancer Institute | 2023 to 2025 | $1,939,839 | April 17, 2023 | March 31, 2028 | CHAREST, ALAIN | reporter.nih.gov |
| The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,938,300 | July 1, 2021 | June 30, 2026 | KOSCHMANN, CARL J | reporter.nih.gov |
| Dissecting the cellular hierarchies of malignant gliomas by single-cell functional genomics | NIH | National Cancer Institute | 2021 to 2025 | $1,931,281 | March 1, 2025 | February 28, 2027 | SUVA, MARIO LUCA | reporter.nih.gov |
| Novel therapeutics for the targeted eradication of DDR-defective tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,929,781 | July 25, 2023 | June 30, 2028 | HERZON, SETH B. | reporter.nih.gov |
| ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas | NIH | National Cancer Institute | 2022 to 2025 | $1,927,713 | August 1, 2022 | July 31, 2027 | WAITKUS, MATTHEW | reporter.nih.gov |
| Engineering T Cell Adoptive Therapy for Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,925,432 | August 1, 2023 | April 30, 2028 | DUNN, GAVIN PETER | reporter.nih.gov |
| The role and mechanism of necrosis in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,916,120 | February 1, 2021 | January 31, 2026 | LI, WEI | reporter.nih.gov |
| Investigation of ecDNA as a driver of intratumoral heterogeneity and treatment resistance in high-risk medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,914,963 | September 1, 2023 | August 31, 2028 | CHAVEZ, LUKAS | reporter.nih.gov |
| Sonobiopsy for Noninvasive Genetic Evaluation of Glioblastoma Patients | NIH | National Cancer Institute | 2023 to 2025 | $1,909,537 | December 1, 2022 | November 30, 2027 | LEUTHARDT, ERIC CLAUDE | reporter.nih.gov |
| Novel multipronged Immunovirotherapy Approach for GBM Treatment | NIH | National Cancer Institute | 2021 to 2025 | $1,909,428 | March 1, 2021 | February 28, 2027 | GALANIS, EVANTHIA | reporter.nih.gov |
| Flow Responsive Embolic Agent for the Complete Devascularization of Meningiomas | NIH | National Cancer Institute | 2021 to 2022 | $1,908,752 | May 15, 2021 | April 30, 2023 | PHAM, QUYNH P | reporter.nih.gov |
| Development and Translation of D-glucose as a Diagnostic Agent for MRI of Cancer | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,905,890 | July 1, 2023 | June 30, 2027 | VAN ZIJL, PETER CM | reporter.nih.gov |
| Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,901,424 | July 15, 2022 | May 31, 2027 | MAHATO, RAM I. | reporter.nih.gov |
| Biophysical Interrogation of Signals that Drive GBM Invasion | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,898,554 | May 1, 2020 | February 28, 2025 | ENGLER, ADAM J | reporter.nih.gov |
| Chitinase-3-like-1 mediated immunosuppression in Glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,897,747 | May 12, 2022 | April 30, 2027 | HU, BAOLI | reporter.nih.gov |
| Innate Antiviral Signals for Cancer Immunotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,895,425 | June 1, 2018 | August 31, 2028 | GROMEIER, MATTHIAS | reporter.nih.gov |
| Mdm2 Alternative Splicing in DNA Damage and Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,893,675 | September 1, 2021 | August 31, 2026 | CHANDLER, DAWN S | reporter.nih.gov |
| Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma | NIH | National Cancer Institute | 2023 to 2025 | $1,886,274 | December 1, 2022 | November 30, 2027 | WOODWORTH, GRAEME F | reporter.nih.gov |
| Elucidating the Role of Perivascular Niche in Glioblastoma Invasion and Therapeutic Resistance at Single Cell Resolution using Biomimetic Tumor Microenvironment Models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,884,981 | September 15, 2021 | July 31, 2027 | NIKKHAH, MEHDI | reporter.nih.gov |
| Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion. | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,884,892 | September 15, 2021 | April 30, 2027 | VAN MEIR, ERWIN G. | reporter.nih.gov |
| Iron Based Coupling Media (IBCM) for MRI-guided Transcranial Ultrasound Surgeries | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,884,663 | September 30, 2022 | June 30, 2027 | ALLEN, STEVEN P | reporter.nih.gov |
| Integrating genome-wide association study data with single-cell `omics' to reveal the cellular effectors of glioblastoma predisposition | NIH | National Cancer Institute | 2025 | $1,882,680 | September 23, 2025 | August 31, 2029 | OSTROM, QUINN T | reporter.nih.gov |
| Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients | NIH | National Cancer Institute | 2021 to 2025 | $1,878,585 | March 9, 2020 | February 28, 2027 | SAROSIEK, KRISTOPHER ANDREW | reporter.nih.gov |
| Transcriptional Regulation in ZFTA-RELA Ependymoma | NIH | National Cancer Institute | 2023 to 2025 | $1,877,375 | August 1, 2023 | July 31, 2028 | MACK, STEPHEN C | reporter.nih.gov |
| Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,872,035 | September 1, 2020 | May 31, 2026 | BOTA, DANIELA ANNENELIE | reporter.nih.gov |
| Radiation-induced vascular reprogramming in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,870,651 | December 15, 2021 | November 30, 2026 | KORNBLUM, HARLEY IAN | reporter.nih.gov |
| Dissecting the biology and consequence of circulating glioma cells | NIH | National Cancer Institute | 2021 to 2024 | $1,870,567 | August 1, 2020 | April 30, 2026 | DORSEY, JAY FITZGERALD | reporter.nih.gov |
| Defining cellular states of quiescence in human brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,865,171 | February 15, 2021 | November 30, 2026 | PADDISON, PATRICK | reporter.nih.gov |
| Tumor 'tractor beam' for diffuse cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,854,880 | September 23, 2021 | August 31, 2026 | MOKARRAM-DORRI, NASSIR | reporter.nih.gov |
| Physiologically Based Pharmacokinetic Modeling of Drug Penetration into the Human Brain and Brain Tumors | NIH | National Cancer Institute | 2021 to 2025 | $1,853,793 | August 1, 2021 | July 31, 2027 | LI, JING | reporter.nih.gov |
| Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy | NIH | National Cancer Institute | 2021 to 2025 | $1,849,109 | May 7, 2021 | April 30, 2026 | MCBRAYER, SAMUEL KENT | reporter.nih.gov |
| Modeling BRAF-fusion driven pediatric brain tumors in the mouse | NIH | National Cancer Institute | 2021 to 2023 | $1,848,656 | June 1, 2019 | May 31, 2024 | VENTURA, ANDREA | reporter.nih.gov |
| Emerging Strategies for Therapy of Metastatic Brain Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,843,587 | August 1, 2024 | July 31, 2031 | LESNIAK, MACIEJ S | reporter.nih.gov |
| Development and Dissemination of Clinical CEST MRI Acquisition and Analysis Methods for Cancer Imaging Applications | NIH | National Cancer Institute | 2021 to 2023 | $1,838,448 | September 12, 2019 | August 31, 2024 | MA, JINGFEI | reporter.nih.gov |
| High-throughput Clinical Hyperpolarized 13C MRI | NIH | Office of the Director, National Institutes of Health | 2025 | $1,835,840 | August 1, 2025 | July 1, 2027 | TSAI, LEO LEE | reporter.nih.gov |
| Deciphering the role of Microglia in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,829,619 | September 22, 2022 | August 31, 2026 | EL-KHOURY, JOSEPH | reporter.nih.gov |
| Homogenized, engineered extracellular vesicles for intracranial targeting | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,828,339 | April 4, 2023 | March 31, 2027 | CARNEY, RANDY | reporter.nih.gov |
| Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,826,791 | September 7, 2022 | August 31, 2028 | MUELLER, SABINE | reporter.nih.gov |
| Quantitative CEST MRI for GBM Early Response Prediction and Biopsy Guidance | NIH | National Cancer Institute | 2021 to 2025 | $1,826,490 | December 15, 2020 | November 30, 2025 | JIANG, SHANSHAN | reporter.nih.gov |
| Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,825,419 | September 15, 2020 | June 30, 2026 | SONABEND, ADAM M | reporter.nih.gov |
| Programming multi-pronged immune response to glioblastoma with IL-13Ra2/TGF-b CAR-T cell therapy. | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,820,675 | March 1, 2023 | January 31, 2028 | CHEN, YVONNE YU-HSUAN | reporter.nih.gov |
| Enhanced Deuterium Metabolic Imaging (DMI) of Metabolic Reprogramming in Brain Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,819,401 | February 1, 2023 | January 31, 2028 | SPIELMAN, DANIEL M | reporter.nih.gov |
| Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,815,797 | September 1, 2019 | January 31, 2025 | VAN MEIR, ERWIN G. | reporter.nih.gov |
| Intraoperative Stereovision for Surgical Guidance | NIH | National Cancer Institute | 2022 to 2024 | $1,814,409 | July 1, 2019 | November 30, 2024 | ROBERTS, DAVID W | reporter.nih.gov |
| Wide-Field Quantitative Fluorescence Imaging System | NIH | National Cancer Institute | 2021 to 2023 | $1,813,186 | September 7, 2022 | February 28, 2025 | ROBERTS, DAVID W | reporter.nih.gov |
| Development of BBB-permeable SUMO1 small molecule degraders for glioblastoma therapy. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,807,663 | March 1, 2022 | February 28, 2027 | HAO, CHUNHAI CHARLIE | reporter.nih.gov |
| Development of B-cell-based vaccine for Glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,802,094 | March 15, 2021 | February 28, 2026 | LEE CHANG, CATALINA | reporter.nih.gov |
| Quantitative molecular MR-PET imaging of glycolysis in glioblastoma | NIH | National Cancer Institute | 2023 to 2025 | $1,802,031 | February 10, 2023 | February 29, 2028 | ELLINGSON, BENJAMIN M. | reporter.nih.gov |
| STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22 | NIH | National Cancer Institute | 2023 to 2025 | $1,791,038 | February 21, 2023 | January 31, 2028 | TRAN, NHAN L | reporter.nih.gov |
| The unique roles of the GTP-binding/protein crosslinking enzyme transglutaminase-2 and signaling partners in aggressive cancers | NIH | National Cancer Institute | 2021 to 2024 | $1,783,848 | December 4, 2015 | April 30, 2026 | CERIONE, RICHARD A. | reporter.nih.gov |
| A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,776,988 | April 1, 2020 | March 31, 2025 | LANG, FREDERICK F | reporter.nih.gov |
| NextGen - CHOP | NIH | National Cancer Institute | 2022 to 2025 | $1,775,451 | June 1, 2025 | May 31, 2026 | MARIS, JOHN M | reporter.nih.gov |
| Mechanisms of adhesion and invasion in hyaluronic acid matrices | NIH | National Cancer Institute | 2021 to 2025 | $1,774,958 | April 1, 2021 | March 31, 2027 | KUMAR, SANJAY | reporter.nih.gov |
| Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,774,749 | December 1, 2022 | November 30, 2027 | QUINONES-HINOJOSA, ALFREDO | reporter.nih.gov |
| Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma | NIH | National Cancer Institute | 2021 to 2023 | $1,768,990 | July 4, 2019 | June 30, 2025 | RUBENSTEIN, JAMES LOUIS | reporter.nih.gov |
| Harnessing YAP-TEAD Activity as Anti-Invasion Therapeutic in Human Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,768,693 | January 15, 2019 | December 31, 2029 | TSANKOVA, NADEJDA MINCHEVA | reporter.nih.gov |
| A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation | NIH | National Cancer Institute | 2023 to 2025 | $1,768,137 | May 5, 2023 | April 30, 2028 | HEIMBERGER, AMY BETH | reporter.nih.gov |
| Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,764,066 | December 9, 2022 | November 30, 2027 | DEBINSKI, WALDEMAR | reporter.nih.gov |
| Radiation-induced senescence in the brain microenvironment: Implications for glioblastoma recurrence and therapy | NIH | National Cancer Institute | 2021 to 2025 | $1,762,474 | April 16, 2021 | March 31, 2027 | BURMA, SANDEEP | reporter.nih.gov |
| Validation of imaging brain tumor metabolism using deuterated glucose | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,757,793 | April 1, 2023 | March 31, 2027 | DE FEYTER, HENK | reporter.nih.gov |
| Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery | NIH | National Cancer Institute | 2021 to 2025 | $1,752,134 | July 9, 2021 | June 30, 2027 | HEANEY, ANTHONY P | reporter.nih.gov |
| Reorienting the Glioblastoma Microenvironment to Respond to Immunotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,750,330 | February 1, 2019 | January 31, 2025 | BARCELLOS-HOFF, MARY HELEN | reporter.nih.gov |
| Microfluidics Array Based Sorting, Isolation, and RNA Analysis in Single Extracellular V csicles | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $1,748,902 | September 10, 2019 | June 30, 2025 | REATEGUI, EDUARDO | reporter.nih.gov |
| Pharmacological targeting of circadian clock components to treat glioblastoma | NIH | National Cancer Institute | 2021 to 2023 | $1,747,149 | September 20, 2019 | August 31, 2024 | PANDA, SATCHIDANANDA | reporter.nih.gov |
| Harnessing Continuous Liquid Interface 3D Printing to Improve Tumor-homing Stem Cell Therapy for Post-surgical Brain Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,735,054 | February 1, 2022 | January 31, 2027 | HINGTGEN, SHAWN | reporter.nih.gov |
| Heterozygous KMT2D Loss and Medulloblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,730,741 | August 9, 2022 | July 31, 2027 | LEE, MIN GYU | reporter.nih.gov |
| Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,730,012 | August 1, 2021 | July 31, 2026 | AINSLIE, KRISTY M | reporter.nih.gov |
| Optimizing Carbon Ion Therapy for Pediatric CNS Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,727,977 | September 18, 2023 | August 31, 2028 | ELEY, JOHN G. | reporter.nih.gov |
| Delineating how retinoic acids regulate lipid metabolism in glioblastoma and their resistance mechanisms | NIH | National Cancer Institute | 2021 to 2024 | $1,723,686 | July 1, 2020 | June 30, 2026 | GUO, DELIANG | reporter.nih.gov |
| Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma Extension | NIH | National Cancer Institute | 2021 to 2025 | $1,723,184 | February 1, 2025 | January 31, 2027 | UNDERHILL, HUNTER REEVE | reporter.nih.gov |
| Chemo-radio immunotherapy for pediatric brain tumors | NIH | National Cancer Institute | 2021 to 2023 | $1,721,832 | September 1, 2019 | August 31, 2025 | MUNN, DAVID H. | reporter.nih.gov |
| Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,721,391 | February 1, 2022 | January 31, 2027 | KOSCHMANN, CARL J | reporter.nih.gov |
| Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,720,248 | September 21, 2023 | May 31, 2028 | READ, RENEE D | reporter.nih.gov |
| Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,718,405 | June 1, 2023 | May 31, 2028 | WEISSLEDER, MD, PHD, RALPH | reporter.nih.gov |
| Targeting IDH mutations to improve seizure control in glioma patients | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,711,983 | August 1, 2020 | April 30, 2026 | HORBINSKI, CRAIG MICHAEL | reporter.nih.gov |
| Circulating cell-free DNA methylation as an accurate tool for detection and clinical follow-up of glioma | NIH | National Cancer Institute | 2023 to 2025 | $1,709,654 | March 10, 2023 | February 29, 2028 | NOUSHMEHR, HOUTAN | reporter.nih.gov |
| Role of Protein Methylation in Cell Mitosis and Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,708,924 | April 15, 2020 | December 31, 2025 | CHENG, SHI-YUAN | reporter.nih.gov |
| Polyamine and Glutamate Driven Interactions in the Glioblastoma-Brain Microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $1,706,819 | August 7, 2015 | January 31, 2027 | WELFORD, SCOTT MICHAEL | reporter.nih.gov |
| MR Fingerprinting based Quantitative Imaging and Analysis Platform (MRF-QIA) for brain tumors. | NIH | National Cancer Institute | 2023 to 2025 | $1,706,274 | January 1, 2023 | December 31, 2028 | GRISWOLD, MARK | reporter.nih.gov |
| Identifying and Targeting the Drivers of Pediatric Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,704,698 | October 1, 2022 | April 30, 2029 | WECHSLER-REYA, ROBERT J. | reporter.nih.gov |
| A randomized controlled phase 2 study of the ketogenic diet for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,703,347 | April 1, 2023 | March 31, 2028 | HU, JETHRO | reporter.nih.gov |
| Retroviral RLI immunomodulatory gene therapy for glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,697,915 | September 1, 2022 | August 31, 2027 | AGHI, MANISH | reporter.nih.gov |
| Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells | NIH | National Cancer Institute | 2023 to 2025 | $1,694,363 | July 1, 2023 | June 30, 2028 | AKHAVAN, DAVID | reporter.nih.gov |
| Bidirectional interaction of platelets and tumor cells in patients with glioblastoma | NIH | National Cancer Institute | 2021 to 2023 | $1,692,983 | December 5, 2018 | August 31, 2025 | SULMAN, ERIK | reporter.nih.gov |
| A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | NIH | National Cancer Institute | 2022 to 2025 | $1,687,964 | March 21, 2022 | February 28, 2027 | LIU, HO-LING ANTHONY | reporter.nih.gov |
| Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma | NIH | National Cancer Institute | 2021 to 2023 | $1,687,302 | September 9, 2019 | August 31, 2025 | BRENNER, ANDREW JACOB | reporter.nih.gov |
| Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma | NIH | National Cancer Institute | 2023 to 2025 | $1,685,761 | April 1, 2023 | March 31, 2028 | SORACE, ANNA C | reporter.nih.gov |
| Deciphering the phosphorylation pattern of RNA polymerase II for eukaryotic transcription | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,684,270 | February 6, 2023 | January 31, 2028 | ZHANG, YAN JESSIE | reporter.nih.gov |
| A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma | NIH | National Cancer Institute | 2022 to 2024 | $1,680,455 | January 1, 2019 | July 31, 2025 | PUDUVALLI, VINAY K | reporter.nih.gov |
| Interleaved 1H/23Na imaging for invasive and proliferative phenotypes of brain tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,672,271 | March 8, 2023 | February 28, 2027 | HYDER, DEWAN SYED FAHMEED | reporter.nih.gov |
| Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,671,259 | September 1, 2021 | August 31, 2025 | KISSIL, JOSEPH | reporter.nih.gov |
| Developing Novel Deep-Learning Based Methods for Deciphering Non-Coding Gene Regulatory Code | NIH | National Library of Medicine | 2021 to 2025 | $1,665,094 | August 1, 2021 | June 30, 2029 | DAVULURI, RAMANA V | reporter.nih.gov |
| A Wireless Multi-function Microscope for Lifetime Imaging of the Brain Tumor Vasculome | NIH | National Cancer Institute | 2021 to 2024 | $1,660,779 | December 12, 2019 | November 30, 2025 | PATHAK, ARVIND P | reporter.nih.gov |
| Harnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to Therapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,660,640 | March 1, 2020 | June 30, 2026 | PERUZZI, PIER PAOLO | reporter.nih.gov |
| Methods to build and annotate tissue atlases using spatial genomic data | NIH | National Human Genome Research Institute | 2024 to 2025 | $1,659,318 | September 5, 2024 | June 30, 2028 | ENGELHARDT, BARBARA | reporter.nih.gov |
| Deciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven Glioma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,653,519 | December 1, 2020 | November 30, 2026 | MACK, STEPHEN C | reporter.nih.gov |
| Integration of 5-ALA Fluorescence Lifetime Imaging with Stereotactic Surgical Navigation for Quantitative Real-Time Spatial Localization of Tumor During Neurosurgical Procedures | NIH | National Cancer Institute | 2023 to 2025 | $1,651,085 | January 1, 2023 | December 31, 2027 | BLOCH, ORIN | reporter.nih.gov |
| Co-targeting S6 and TAM kinases in PTEN-deficient glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,649,215 | December 11, 2019 | November 30, 2025 | PLAS, DAVID R | reporter.nih.gov |
| Decoding the molecular basis of cellular identity in adult malignant gliomas | NIH | National Cancer Institute | 2021 to 2024 | $1,644,542 | December 1, 2019 | November 30, 2025 | OLDHAM, MICHAEL CLARK | reporter.nih.gov |
| Regulation, function, and the therapeutic potential of an oncogenic long noncoding RNA lnc-HLX-2-7 in group 3 medulloblastomas | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,640,984 | July 15, 2022 | June 30, 2027 | PERERA, RANJAN JOSEPH | reporter.nih.gov |
| Mechanisms of resistance to WEE1 inhibition in Myc driven medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,638,259 | April 1, 2015 | November 30, 2026 | VIBHAKAR, RAJEEV | reporter.nih.gov |
| Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities | NIH | National Cancer Institute | 2024 to 2025 | $1,637,935 | July 1, 2024 | June 30, 2026 | CHOWDHURY, DIPANJAN | reporter.nih.gov |
| Fatty Acid Metabolic Regulation of Anti-Tumor Immunity Against Irradiated Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,632,860 | June 1, 2023 | May 31, 2028 | VANPOUILLE-BOX, CLAIRE ISABELLE | reporter.nih.gov |
| Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors | NIH | National Cancer Institute | 2021 to 2023 | $1,631,503 | September 2, 2019 | August 31, 2024 | LI, GORDON | reporter.nih.gov |
| Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,629,124 | September 19, 2023 | July 31, 2027 | LJUBIMOV, ALEXANDER V | reporter.nih.gov |
| Pro-Drug Enolase Inhibitors in Precision Oncology | NIH | National Cancer Institute | 2021 to 2025 | $1,618,674 | February 8, 2021 | January 31, 2027 | MILLWARD, STEVEN W | reporter.nih.gov |
| Investigating the role of dysfunctional histone H3.3 in driving early neuronal development and pediatric high-grade gliomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,617,011 | June 1, 2021 | November 30, 2026 | HU, JIAN | reporter.nih.gov |
| The Role of GABA Transaminase ABAT in Pediatric Brain Tumor Medulloblastoma Development and Spread | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,613,377 | June 1, 2023 | February 28, 2028 | NEMAN-EBRAHIM, JOSH | reporter.nih.gov |
| Development of Quantitative Deuterium MRS Imaging for Human Brain Tumor Application at Ultrahigh Field | NIH | National Cancer Institute | 2021 to 2025 | $1,611,851 | August 1, 2019 | July 31, 2027 | CHEN, WEI | reporter.nih.gov |
| Bimodal EGFR signaling in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,610,520 | January 1, 2022 | December 31, 2026 | HABIB, AMYN | reporter.nih.gov |
| Delineation of the natural history of Ollier disease and Muffucci syndrome and investigation of their genetic bases | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,607,138 | February 1, 2023 | January 31, 2028 | SOBREIRA, NARA | reporter.nih.gov |
| Reprograming Macrophages and Targeting Glioma Stem Cells in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,597,925 | August 1, 2022 | July 31, 2027 | BAO, SHIDENG | reporter.nih.gov |
| Preoperative Image Updating for Guidance during Brain Tumor Resection | NIH | National Cancer Institute | 2021 to 2023 | $1,593,244 | April 4, 2011 | February 28, 2025 | PAULSEN, KEITH D. | reporter.nih.gov |
| Chemical Genetic Approaches to Study Chromatin Complexes | NIH | National Cancer Institute | 2023 to 2025 | $1,590,400 | May 3, 2023 | April 30, 2028 | LIAU, BRIAN | reporter.nih.gov |
| Regulation of Angpt1 and DIPG blood-brain barrier integrity by H3K27M mutations | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,587,577 | December 15, 2021 | November 30, 2026 | PHOENIX, TIMOTHY N | reporter.nih.gov |
| Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma | NIH | National Cancer Institute | 2022 to 2025 | $1,584,966 | September 21, 2022 | August 31, 2026 | SOHER, BRIAN J | reporter.nih.gov |
| Vulnerabilities of MMR-deficient glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,584,018 | August 1, 2022 | July 31, 2027 | PUROW, BENJAMIN W. | reporter.nih.gov |
| Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomas | NIH | National Cancer Institute | 2021 to 2022 | $1,582,753 | August 22, 2018 | July 31, 2024 | CARTER, BOB S | reporter.nih.gov |
| Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,582,376 | September 1, 2023 | August 31, 2028 | BADIE, BEHNAM | reporter.nih.gov |
| Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma | NIH | National Cancer Institute | 2023 to 2025 | $1,581,237 | January 1, 2023 | December 31, 2027 | VADLAMUDI, RATNA K | reporter.nih.gov |
| Targeting Lag-3 and PD -1 in Myeloid Cells of GBM | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,580,147 | April 1, 2022 | March 31, 2027 | LIM, MICHAEL | reporter.nih.gov |
| Glioma intelligence from behind enemy lines | NIH | National Cancer Institute | 2023 to 2025 | $1,580,138 | March 1, 2023 | February 29, 2028 | BURNS, TERRY | reporter.nih.gov |
| Quantitative (Perfusion and Diffusion) MRI Biomarkers to Measure Glioma Response | NIH | National Cancer Institute | 2021 to 2023 | $1,576,805 | February 28, 2014 | August 31, 2024 | SCHMAINDA, KATHLEEN MARIE | reporter.nih.gov |
| Next Gen Virotherapy for GBM | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,572,806 | July 1, 2022 | June 30, 2027 | KAUR, BALVEEN | reporter.nih.gov |
| Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,572,445 | April 1, 2022 | March 31, 2027 | ZADEH, GELAREH | reporter.nih.gov |
| “Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response” | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,569,424 | September 19, 2023 | August 31, 2028 | ROSTOMILY, ROBERT C | reporter.nih.gov |
| Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay | NIH | National Cancer Institute | 2021 to 2024 | $1,568,754 | June 1, 2020 | May 31, 2026 | BOMSZTYK, KAROL | reporter.nih.gov |
| Role of meningeal lymphatic vasculature in neuroimmune communication development | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,566,735 | February 15, 2023 | January 31, 2028 | THOMAS, JEAN-LEON | reporter.nih.gov |
| Role of ER Stress and Fatty Acid Metabolism in Glioma Stem Cells | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,562,282 | September 15, 2020 | July 31, 2026 | BADR, CHRISTIAN ELIAS | reporter.nih.gov |
| Chemical approaches for generating blood-brain barrier-permeable antibody conjugates | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,560,000 | September 5, 2020 | July 31, 2025 | TSUCHIKAMA, KYOJI | reporter.nih.gov |
| IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells | NIH | National Cancer Institute | 2021 to 2022 | $1,557,154 | February 3, 2016 | January 31, 2024 | BALDWIN, ALBERT SIDNEY | reporter.nih.gov |
| Ionic Liquid-Coated NIR-II Polymer Conjugates as Targeted Brain Theranostics | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $1,556,797 | September 26, 2022 | June 30, 2025 | WATKINS, DAVITA L. | reporter.nih.gov |
| Sonic Hedgehog Signaling in Neocortical Growth and Folding | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,554,342 | September 30, 2017 | December 31, 2028 | HAN, YOUNG-GOO | reporter.nih.gov |
| Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant Glioma | NIH | National Cancer Institute | 2023 to 2025 | $1,553,525 | September 4, 2023 | August 31, 2028 | CUI, HONGGANG | reporter.nih.gov |
| Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,551,678 | January 1, 2022 | December 31, 2026 | MCCARTY, JOSEPH H | reporter.nih.gov |
| Whole-brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields | NIH | National Cancer Institute | 2021 to 2025 | $1,547,216 | September 1, 2021 | May 31, 2027 | MOHAN, SUYASH | reporter.nih.gov |
| Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,544,794 | September 1, 2022 | August 31, 2027 | LU, RONGZE OLIVIA | reporter.nih.gov |
| Comparison of convection enhanced delivery systems in a randomized controlled clinical study of recurrent Grade 3-4 glioma patients | NIH | National Cancer Institute | 2024 to 2025 | $1,539,437 | September 1, 2024 | August 31, 2027 | ABRAMOV, VASILIY | reporter.nih.gov |
| Mechanisms of SOX2 Regulation in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,530,539 | August 15, 2022 | July 31, 2027 | KIM, ALBERT HONG-JAE | reporter.nih.gov |
| Optimizing demethylating therapy for IDH1 Mutant Malignant Gliomas | NIH | National Cancer Institute | 2021 to 2024 | $1,530,510 | May 15, 2015 | January 31, 2025 | RIGGINS, GREGORY JOSEPH | reporter.nih.gov |
| Hydrogen sulfide functions as a tumor suppressor in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,529,987 | April 1, 2023 | February 29, 2028 | HINE, CHRISTOPHER MICHAEL | reporter.nih.gov |
| Biophysical Control of Cell Form and Function by Single Actomyosin Stress Fibers | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,528,520 | September 20, 2017 | April 30, 2027 | KUMAR, SANJAY | reporter.nih.gov |
| Molecular mechanisms of nucleic acid machines | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,520,008 | June 1, 2020 | May 31, 2026 | ENEMARK, ERIC | reporter.nih.gov |
| Nanocage-based systemic delivery of TGFβ trap for immunomodulation of brain neoplasms | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,518,429 | May 1, 2021 | August 25, 2023 | SUK, JUNG SOO | reporter.nih.gov |
| Polyketides via Redox-Triggered Alcohol C-H Functionalization | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,515,454 | May 1, 2011 | May 31, 2025 | KRISCHE, MICHAEL J | reporter.nih.gov |
| Ultra-high precision image-guided incisionless transcranial ultrasound surgery | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,514,111 | August 20, 2024 | April 30, 2028 | PINTON, GIANMARCO | reporter.nih.gov |
| Generation of Intermediate Neural Progenitors in Drosophila Larval Brains | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,511,379 | September 30, 2014 | April 30, 2026 | ZHU, SIJUN | reporter.nih.gov |
| Oncometabolites, DNA Repair, and Cancer | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $1,507,500 | September 30, 1992 | December 31, 2026 | GLAZER, PETER M | reporter.nih.gov |
| IDO1 and Immunotolerance in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,505,262 | August 1, 2016 | June 30, 2027 | WAINWRIGHT, DEREK ALAN | reporter.nih.gov |
| Nanoformulated small molecule immunotherapy for SHH medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,504,463 | January 1, 2022 | December 31, 2026 | SOKOLSKY-PAPKOV, MARINA | reporter.nih.gov |
| Development of Novel MNK Inhibitors for Treating Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,503,510 | September 1, 2019 | June 30, 2024 | PLATANIAS, LEONIDAS C. | reporter.nih.gov |
| Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of Radiotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,501,570 | July 1, 2023 | June 30, 2028 | PAJONK, FRANK | reporter.nih.gov |
| Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity | NIH | National Cancer Institute | 2023 to 2025 | $1,499,435 | July 15, 2023 | June 30, 2028 | PFEFFER, LAWRENCE MARC | reporter.nih.gov |
| Targeting epigenetic reader GAS41 | NIH | National Cancer Institute | 2021 to 2023 | $1,498,524 | April 1, 2020 | March 31, 2026 | CIERPICKI, TOMASZ | reporter.nih.gov |
| A RIPK2-Targeting Apoptosis-Inducing Small Molecule for the Treatment of Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,492,646 | June 1, 2019 | March 31, 2024 | LAIRSON, LUKE LEE | reporter.nih.gov |
| Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | NIH | National Cancer Institute | 2022 to 2023 | $1,492,571 | May 24, 2010 | February 29, 2024 | UNGER, EVAN CHARLES | reporter.nih.gov |
| Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,491,962 | April 1, 2022 | March 31, 2027 | JAIN, RAKESH K. | reporter.nih.gov |
| Role of the collagen receptor LAIR-1 in glioma progression and the tumor immune microenvironment | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,491,496 | March 1, 2022 | February 28, 2027 | LOWENSTEIN, PEDRO R. | reporter.nih.gov |
| Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme | NIH | National Cancer Institute | 2023 to 2025 | $1,491,029 | April 1, 2023 | August 31, 2027 | MARCUS, STUART | reporter.nih.gov |
| Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,489,978 | May 1, 2020 | April 30, 2025 | LESNIAK, MACIEJ S | reporter.nih.gov |
| MAPK as target of glioma immunoediting by CD8 T-cells, and predictor of response to immunotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,489,587 | April 15, 2020 | December 31, 2025 | SONABEND, ADAM M | reporter.nih.gov |
| Regulation of the Hedgehog pathway and Medulloblastoma response to radiochemotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,482,576 | April 15, 2021 | February 28, 2027 | PEI, HUADONG | reporter.nih.gov |
| Unravelling metabolic dependencies in H3K27M mutant DIPG | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,480,728 | September 1, 2019 | August 31, 2029 | VENNETI, SRIRAM | reporter.nih.gov |
| Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $1,473,715 | August 2, 2019 | June 30, 2025 | SIRIANNI, RACHAEL W | reporter.nih.gov |
| Optical Genome Mapping As a Novel Diagnostic Approach in Pediatric Brain Tumors | NIH | National Cancer Institute | 2024 to 2025 | $1,472,734 | July 23, 2024 | June 30, 2029 | BORNHORST, MIRIAM A. | reporter.nih.gov |
| Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid | NIH | National Cancer Institute | 2021 to 2024 | $1,472,093 | July 1, 2018 | June 30, 2025 | BETTEGOWDA, CHETAN | reporter.nih.gov |
| Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatment | NIH | National Cancer Institute | 2021 to 2023 | $1,469,469 | July 4, 2019 | June 30, 2024 | LAWLER, SEAN EDWARD | reporter.nih.gov |
| An informatics framework for single-cell multi-omics from clinical specimens | NIH | National Library of Medicine | 2022 to 2025 | $1,468,819 | July 1, 2022 | March 31, 2027 | DIAZ, AARON ANTONIO | reporter.nih.gov |
| The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,468,733 | June 1, 2020 | May 31, 2025 | HABIB, AMYN | reporter.nih.gov |
| Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,467,722 | September 1, 2020 | May 31, 2025 | DANIELS, DAVID | reporter.nih.gov |
| Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects | NIH | National Cancer Institute | 2021 to 2024 | $1,463,670 | July 1, 2020 | June 30, 2026 | GUPTA, NALIN | reporter.nih.gov |
| Molecular basis for the impact of sex on brain tumorigenesis | NIH | National Cancer Institute | 2021 to 2024 | $1,462,584 | May 1, 2014 | June 30, 2025 | RUBIN, JOSHUA B | reporter.nih.gov |
| Targeting extracellular signaling-regulated kinase 5 (ERK5) in brain tumors and their microenvironment | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,459,165 | April 1, 2020 | January 31, 2026 | AGNIHOTRI, SAMEER | reporter.nih.gov |
| Targeting Glioblastoma with a Nuclear-penetrating Anti-DNA Autoantibody | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,454,633 | April 1, 2020 | January 31, 2026 | HANSEN, JAMES E. | reporter.nih.gov |
| PET Biomarker for synaptic density changes after radiation therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,454,243 | September 3, 2024 | August 31, 2028 | ABOIAN, MARIAM | reporter.nih.gov |
| Transcriptional control of OPC fate specification and homing to gray matter and white matter in the CNS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,439,955 | April 1, 2022 | March 31, 2027 | VUE, TOU YIA | reporter.nih.gov |
| Nano-therapeutics Reprogramming of Immunosuppressive Myeloid Cells Potentiate Radiotherapy for Glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,438,381 | July 26, 2022 | June 30, 2027 | ZHANG, PENG | reporter.nih.gov |
| Modulation of Microglia and T Cell Interactions in Malignant Glioma | NIH | National Cancer Institute | 2021 to 2025 | $1,434,490 | January 10, 2007 | June 30, 2026 | HEIMBERGER, AMY BETH | reporter.nih.gov |
| UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS | NIH | National Cancer Institute | 2021 to 2022 | $1,434,176 | September 4, 2018 | August 31, 2024 | JENKINS, ROBERT B. | reporter.nih.gov |
| Identifying SREBP-1 activation mechanism in glioblastoma and its new role in regulating glutamine metabolism | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,427,186 | April 1, 2020 | January 31, 2026 | GUO, DELIANG | reporter.nih.gov |
| Targeting oncogenic dopamine receptor signaling in glioblastoma | NIH | National Cancer Institute | 2021 to 2023 | $1,424,613 | December 6, 2018 | November 30, 2024 | LEE, JEONGWU | reporter.nih.gov |
| Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | NIH | National Cancer Institute | 2024 to 2025 | $1,424,418 | April 1, 2024 | March 31, 2029 | DANIAL, NIKA N | reporter.nih.gov |
| AHR-mediated immunosuppression in glioblastoma | NIH | National Institute of Environmental Health Sciences | 2021 to 2023 | $1,422,141 | September 1, 2019 | July 31, 2025 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Epigenetic pathways and cell cycle exit | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,421,268 | August 1, 2020 | May 31, 2025 | AYAD, NAGI G | reporter.nih.gov |
| Regulation of CNS angiogenesis and barriergenesis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,420,544 | April 15, 2020 | February 28, 2025 | TAYLOR, MICHAEL ROBERT | reporter.nih.gov |
| TRPM7 induces tumorigenesis and stemness through Notch activation in glioma | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,420,000 | April 11, 2022 | March 31, 2027 | LIU, MINGLI | reporter.nih.gov |
| Translational Application of Magnetic Hyperthermia Therapy with Adjuvant Therapies for Glioblastoma | NIH | National Cancer Institute | 2021 to 2022 | $1,419,392 | December 1, 2019 | September 30, 2022 | HADJIPANAYIS, CONSTANTINOS GEORGE | reporter.nih.gov |
| Towards intra-operative guidance in brain tumor surgery using real-time resting-state functional MRI | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,406,555 | September 19, 2023 | August 31, 2028 | DENNIG, DIETER W | reporter.nih.gov |
| Oncogenic mechanisms underlying GLI2-amplified medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,403,616 | March 16, 2023 | February 29, 2028 | PEI, YANXIN | reporter.nih.gov |
| MR-Guided Precision Conformal Ablation Therapy for Brain Tumors | NIH | National Cancer Institute | 2021 to 2022 | $1,400,508 | May 17, 2013 | August 31, 2025 | ZHANG, HAICHONG | reporter.nih.gov |
| SON-mediated RNA splicing in glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,396,874 | July 1, 2020 | June 30, 2025 | AHN, ERIN EUN-YOUNG | reporter.nih.gov |
| Chemical Exchange Saturation Transfer MR Fingerprinting | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,395,888 | September 21, 2021 | June 30, 2026 | HEO, HYE YOUNG | reporter.nih.gov |
| Epigenetic regulation of LDOC1 drives tumor biology in high risk ependymoma | NIH | National Cancer Institute | 2021 to 2024 | $1,390,812 | July 1, 2020 | June 30, 2025 | FOREMAN, NICHOLAS K | reporter.nih.gov |
| Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBM | NIH | National Cancer Institute | 2023 to 2025 | $1,386,369 | June 1, 2023 | May 31, 2028 | GOSWAMI, SANGEETA | reporter.nih.gov |
| Engineer Biomimetic Microfluidic Models to Investigate and Reprogram Tumor Associated Neutrophils for Cancer Therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,385,581 | July 15, 2022 | June 30, 2027 | BAO, XIAOPING | reporter.nih.gov |
| Long term radiation treatment planning in brain tumors in the pediatric population | NIH | National Cancer Institute | 2024 to 2025 | $1,384,140 | July 1, 2024 | June 30, 2027 | LOW, JUSTIN | reporter.nih.gov |
| Core Laboratory for Advanced Cancer Image Analysis | NIH | National Cancer Institute | 2021 to 2025 | $1,378,272 | September 19, 2017 | August 31, 2027 | MUZI, MARK | reporter.nih.gov |
| NAD+ Pathway Signaling in Glioblastoma Tumor Growth and Therapy Resistance | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,377,703 | July 1, 2019 | June 30, 2025 | KIM, ALBERT HONG-JAE | reporter.nih.gov |
| White Matter Toxicity and Neurocognitive Outcomes in Pediatric Brain Tumor Patients Treated with Proton Beam Radiation Therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,376,955 | June 16, 2017 | November 30, 2024 | KAHALLEY, LISA SCHUM | reporter.nih.gov |
| Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma | NIH | National Cancer Institute | 2021 to 2022 | $1,374,608 | July 1, 2018 | June 30, 2023 | CHAREST, ALAIN | reporter.nih.gov |
| Translational Application of Magnetic Hyperthermia Therapy with Adjuvant Therapies for Glioblastoma | NIH | National Cancer Institute | 2023 to 2024 | $1,372,507 | December 1, 2019 | November 30, 2025 | HADJIPANAYIS, CONSTANTINOS GEORGE | reporter.nih.gov |
| Bone marrow-derived myeloid cell dysregulation in malignant progression of glioma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,369,162 | July 15, 2023 | May 31, 2028 | RAJAPPA, PRAJWAL | reporter.nih.gov |
| Identifying and Targeting 3D Regulatory Nodes that Maintain Glioblastoma Programs | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,368,605 | May 1, 2024 | April 30, 2029 | APOSTOLOU, EFFIE | reporter.nih.gov |
| Epigenetic re-establishment of tumor suppression in glioblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,357,758 | July 1, 2024 | June 30, 2029 | MILLS, ALEA A. | reporter.nih.gov |
| Cellular and Molecular Mechanisms of GBM Infiltration | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,356,472 | March 15, 2022 | February 28, 2027 | DENEEN, BENJAMIN | reporter.nih.gov |
| Therapeutic Targeting of WDR5 in the Glioblastoma Perivascular Niche | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,356,057 | August 1, 2023 | May 31, 2028 | HUBERT, CHRISTOPHER G | reporter.nih.gov |
| An Integrated CT-based Image-Guided Neurosurgical System | NIH | National Cancer Institute | 2021 | $1,355,820 | May 1, 2005 | August 31, 2023 | VANKAMPEN, WILLIAM CHARLES | reporter.nih.gov |
| Identifying and Targeting the Drivers of Pediatric Brain Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,353,600 | May 1, 2021 | August 31, 2022 | WECHSLER-REYA, ROBERT J. | reporter.nih.gov |
| Regulation of Tumor Immunogenicity in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,352,288 | April 1, 2023 | February 29, 2028 | HO, SZE CHUN WINSON | reporter.nih.gov |
| MECHANISMS OF POL II ELONGATION IN DIFFUSE MIDLINE GLIOMA | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,350,144 | February 15, 2023 | January 31, 2028 | ANASTAS, JAMIE N. | reporter.nih.gov |
| Image-based Systems Biology of Vascular Co-option in Brain Tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,340,709 | April 27, 2023 | March 31, 2028 | PATHAK, ARVIND P | reporter.nih.gov |
| Evolution and targeting of the functional states of glioblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,339,076 | July 1, 2022 | June 30, 2027 | LASORELLA, ANNA | reporter.nih.gov |
| Combination metabolic therapy for diffuse midline glioma | NIH | National Cancer Institute | 2024 to 2025 | $1,335,041 | August 7, 2024 | July 31, 2029 | VISWANATH, PAVITHRA | reporter.nih.gov |
| Brain-Restricted Kinase Inhibition with Binary Pharmacology | NIH | National Cancer Institute | 2024 to 2025 | $1,334,525 | March 1, 2024 | February 28, 2029 | WEISS, WILLIAM A | reporter.nih.gov |
| Bystander gene deletions in cancer: mechanisms of therapeutic opportunities and challenges | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,333,211 | December 1, 2019 | August 31, 2024 | DASGUPTA, BIPLAB | reporter.nih.gov |
| Developing therapeutic strategies to elicit metabolic synthetic lethality in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,327,277 | December 1, 2019 | November 30, 2025 | CHINNAIYAN, PRAKASH | reporter.nih.gov |
| Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,324,369 | September 15, 2020 | June 30, 2025 | FLORES, CATHERINE T | reporter.nih.gov |
| Random Matrix Theory-Based Noise Removal in MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,324,171 | September 16, 2019 | July 31, 2025 | NOVIKOV, DMITRY S | reporter.nih.gov |
| Epigenetic dependence of diffuse midline glioma with H3K27M mutation | NIH | National Cancer Institute | 2023 to 2025 | $1,321,553 | September 1, 2023 | August 31, 2028 | ZHANG, ZHIGUO | reporter.nih.gov |
| Roles of Chromatin Remodeler CHD2 in Diffuse Midline Glioma with Onco-Histone Mutations | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,318,863 | March 20, 2023 | February 29, 2028 | ZHANG, ZHIGUO | reporter.nih.gov |
| Mechanisms of Biguanide Sensitivity in GBM | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,317,690 | February 1, 2016 | November 30, 2024 | DASGUPTA, BIPLAB | reporter.nih.gov |
| Epigenetically regulated stemness program and stem cell niche as targets in pediatric DIPG | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,308,288 | June 1, 2023 | April 30, 2028 | GALBAN, STEFANIE | reporter.nih.gov |
| Targeting mechanosignaling in pediatric brain cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,305,806 | February 14, 2022 | January 31, 2027 | LANGHANS, SIGRID A | reporter.nih.gov |
| Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,305,576 | September 19, 2024 | August 31, 2029 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Mitochondria electron transport chain complexes adaptative responses to cellular stress | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,304,730 | July 1, 2023 | June 30, 2028 | GRIGUER, CORINNE E. | reporter.nih.gov |
| Novel wearable rotating magnetic field therapy device targeting treatment of brain cancers | NIH | National Cancer Institute | 2025 | $1,296,385 | September 18, 2025 | August 31, 2027 | GOWDA, ASHOK | reporter.nih.gov |
| Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,291,746 | July 5, 2024 | June 30, 2029 | JIANG, WEN | reporter.nih.gov |
| Novel Piezoelectric Amino-acid Ultrasound Transducer to Deliver Drugs Through the Blood Brain Barrier | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,290,469 | February 15, 2023 | January 31, 2028 | NGUYEN, THANH | reporter.nih.gov |
| Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,289,448 | July 28, 2023 | June 30, 2028 | GROMEIER, MATTHIAS | reporter.nih.gov |
| Immune dysregulation mechanisms of persistent post-COVID19 olfactory dysfunction | NIH | National Institute on Deafness and Other Communication Disorders | 2024 to 2025 | $1,287,704 | July 1, 2024 | June 30, 2029 | BANKOVA, LORA | reporter.nih.gov |
| Metabolic Reprogramming in Brain Tumors | NIH | National Cancer Institute | 2021 to 2022 | $1,287,027 | February 5, 2013 | February 29, 2024 | RONEN, SABRINA MIRIAM | reporter.nih.gov |
| Development and validation of an autologous mouse model for the study of immune interactions with glioblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,286,799 | June 3, 2024 | May 31, 2029 | BINDER, ZEV ARI | reporter.nih.gov |
| A Bioprinted Volumetric Model of Vascularized Glioblastoma | NIH | National Cancer Institute | 2023 to 2025 | $1,278,707 | September 14, 2023 | August 31, 2028 | ZHANG, Y. SHRIKE | reporter.nih.gov |
| Development of Validation of Phage-Displayed Random Peptide Libraries Technologies for Rapid Isolation and Characterization of Extracellular Vesicles from Patients with Brain Tumors | NIH | National Institute of Mental Health | 2021 to 2022 | $1,277,725 | September 18, 2018 | August 31, 2024 | GRANER, MICHAEL W. | reporter.nih.gov |
| Genetic control of neural stem cell homeostasis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,276,374 | September 30, 2013 | April 30, 2028 | LU, BINGWEI | reporter.nih.gov |
| Enhancing cell therapy for brain tumors | NIH | National Cancer Institute | 2021 to 2022 | $1,273,273 | September 30, 2018 | August 31, 2024 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Therapeutic targeting mesenchymal transition in newly diagnosed and recurrent GBM | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,273,013 | September 15, 2024 | August 31, 2028 | FURNARI, FRANK | reporter.nih.gov |
| Single-cell genomic approaches to study the cellular origins of brain tumors | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $1,271,250 | September 16, 2019 | August 31, 2024 | EVRONY, GILAD DAVID | reporter.nih.gov |
| Role of RBBP4/p300 Complex in Recovery from therapy induced DNA damage in glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,269,659 | April 1, 2022 | June 30, 2026 | KITANGE, GASPAR JULIUS | reporter.nih.gov |
| Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model | NIH | National Cancer Institute | 2024 to 2025 | $1,269,486 | July 1, 2024 | June 30, 2028 | LI, YUANPEI | reporter.nih.gov |
| Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,267,312 | August 22, 2024 | July 31, 2029 | CHIOCCA, E. ANTONIO | reporter.nih.gov |
| Stroger Hospital of Cook County (SHCC) NCORP | NIH | National Cancer Institute | 2024 to 2025 | $1,264,793 | August 16, 2014 | July 31, 2026 | TAMKUS, DEIMANTE | reporter.nih.gov |
| Mechanisms and Function of Autophagy in Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,262,588 | January 1, 2013 | December 31, 2023 | JIANG, XUEJUN | reporter.nih.gov |
| Molecular and cellular mechanisms of neuronal damage caused by anticancer therapies | NIH | National Cancer Institute | 2024 to 2025 | $1,261,134 | March 1, 2024 | February 28, 2029 | DUMAN, JOSEPH G | reporter.nih.gov |
| Transcranial Magnetic Resonance guided Histotripsy (tcMRgHt) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,259,901 | August 1, 2019 | April 30, 2024 | XU, ZHEN | reporter.nih.gov |
| Therapeutic Potential of a Novel MGMT-Dependent DNA Interstrand Crosslinking Agent in the Treatment of DNA Repair Deficient Cancer | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $1,256,250 | September 20, 2023 | July 31, 2028 | GUEBLE, SUSAN E | reporter.nih.gov |
| IDO1 and Immunotolerance in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,255,330 | August 1, 2016 | December 31, 2022 | WAINWRIGHT, DEREK ALAN | reporter.nih.gov |
| Oncolytic HSV Immunovirotherapy for brain tumors | NIH | National Cancer Institute | 2024 to 2025 | $1,254,552 | July 15, 2024 | June 30, 2029 | MARTUZA, ROBERT L | reporter.nih.gov |
| Identification of Germline Modifiers of Neurofibromatosis Type 1 Tumors | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,254,291 | September 10, 2024 | August 31, 2029 | RATNER, NANCY | reporter.nih.gov |
| Integration of CSF Proteogenomics in the Diagnosis and Management of Diffuse Gliomas | NIH | National Cancer Institute | 2024 to 2025 | $1,253,576 | July 3, 2024 | June 30, 2029 | MANSOURI, ALIREZA | reporter.nih.gov |
| MOLECULAR DISSECTION OF SEIZURE MICROENVIRONMENT IN MALIGNANT GLIOMA | NIH | National Cancer Institute | 2021 to 2022 | $1,251,618 | December 15, 2017 | November 30, 2023 | NOEBELS, JEFFREY | reporter.nih.gov |
| dMRI-guided pre-operative planning for supra-total resection of high-gradegliomas | NIH | National Cancer Institute | 2023 to 2025 | $1,243,351 | August 22, 2023 | August 31, 2029 | VERMA, RAGINI | reporter.nih.gov |
| Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma | NIH | National Cancer Institute | 2021 to 2023 | $1,241,760 | December 1, 2019 | March 31, 2023 | VERHAAK, ROEL GW | reporter.nih.gov |
| The role of membrane homoeostasis of neural stem cell and glioma stem cells in neural development and gliomagenesis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,240,371 | August 21, 2023 | May 31, 2028 | HU, JIAN | reporter.nih.gov |
| Enhanced Delivery of Cytotoxic Neural Stem Cells for Treatment of Glioblastoma Multiforme Using an Innovative In-situ Thermogelling Hydrogel and Focused Ultrasound | NIH | National Cancer Institute | 2024 to 2025 | $1,233,216 | September 13, 2024 | August 31, 2029 | BENHABBOUR, SOUMYA RAHIMA | reporter.nih.gov |
| Radiomic spatial maps for identifying viable tumor extent on multi-parametric MRI for Glioblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,226,407 | June 1, 2024 | May 31, 2026 | TIWARI, PALLAVI | reporter.nih.gov |
| Role of SMARCD3/BAF60C in medulloblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,224,211 | August 1, 2024 | June 30, 2029 | HU, BAOLI | reporter.nih.gov |
| Neural Activity Signatures of Tumor Infiltration in the Human Brain | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,217,078 | September 1, 2024 | July 31, 2029 | PAULK, ANGELIQUE C | reporter.nih.gov |
| Nanotherapeutic treatment of the invasive glioblastoma microenvironment | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,216,176 | March 15, 2019 | December 31, 2024 | WOODWORTH, GRAEME F | reporter.nih.gov |
| Identification and cloning of neoantigen-specific T cells for GBM immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,215,592 | April 1, 2019 | March 31, 2025 | PRINS, ROBERT M | reporter.nih.gov |
| Targeting metabolic dependencies in ZFTA-RELA fusion childhood ependymomas | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,207,087 | August 15, 2023 | July 31, 2028 | VENNETI, SRIRAM | reporter.nih.gov |
| Tissue-Engineered Models of Glioblastoma for Evaluating Treatment Response | NIH | National Cancer Institute | 2022 to 2024 | $1,205,337 | February 13, 2020 | January 31, 2025 | SEIDLITS, STEPHANIE KRISTIN | reporter.nih.gov |
| Discovering the mechanisms underlying oncogenesis by ZFTA-RELA and pinpointing therapeutic targets. | NIH | National Cancer Institute | 2024 to 2025 | $1,202,500 | September 13, 2024 | August 31, 2029 | MACK, STEPHEN C | reporter.nih.gov |
| The role of Olig2 in the tumorigenesis, progression and metastasis in MYC-amplified medulloblastoma | NIH | National Cancer Institute | 2021 to 2023 | $1,202,288 | August 7, 2019 | July 31, 2025 | PEI, YANXIN | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 671 | $347,357,227 | 0 | $0 |
| 2024 | 709 | $321,526,494 | 0 | $0 |
| 2023 | 694 | $313,682,613 | 0 | $0 |
| 2022 | 698 | $296,052,801 | 0 | $0 |
| 2021 | 660 | $278,642,167 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.